HOUSE DOCKET, NO. 381        FILED ON: 1/14/2011

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 681

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Viriato Manuel deMacedo

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act Regulating Appeals under the Group Insurance Commission..

_______________

PETITION OF:

 

Name:

District/Address:

Date Added:

Viriato Manuel deMacedo

1st Plymouth

1/14/2011

Sheila C. Harrington

1st Middlesex

2/3/2011


HOUSE DOCKET, NO. 381        FILED ON: 1/14/2011

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 681

By Mr. deMacedo of Plymouth, a petition (accompanied by bill, House, No. 681) of Viriato Manuel deMacedo and Sheila C. Harrington regulating appeals under the group insurance commission.  Public Service.

 

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE HOUSE, NO. 2351 OF 2009-2010.]

 

The Commonwealth of Massachusetts

 

_______________

In the Year Two Thousand Eleven

_______________

 

An Act Regulating Appeals under the Group Insurance Commission..

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1.  Chapter 32A of the General Laws is hereby by amended, at the end thereof, the following new section:-

Section 17K. Any person who is dispensed a non-formulary or non-preferred brand name prescription drug, as determined under a pharmaceutical drug program established by the commission or through a pharmacy benefit manager contracted by the commission, may appeal that determination to the commission, and upon the submission of a statement by the person’s physician that, due to a medical necessity, only the non-formulary or non-preferred brand name prescription drug can be dispensed, the person shall pay for the drug at the same rate required for the formulary or preferred brand name prescription drugs under such pharmaceutical drug program.